Search Articles
Cell Genesys is selling itself too cheaply to BioSante Pharmaceuticals, in a stock swap valued at $38 million, shareholders say in Delaware Chancery Court.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.